Article Text

Download PDFPDF
Using AChR antibody titres to predict treatment responses in myasthenia gravis
  1. Angela Vincent
  1. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  1. Correspondence to Professor Angela Vincent, University of Oxford, Oxford OX1 2JD, UK; angela.vincent{at}ndcn.ox.ac.uk

Statistics from Altmetric.com

Serial antibody measurements can be helpful as a guide to treatment responses but the titres need to be performed appropriately

Detection of a specific antibody in the serum (and cerebrospinal fluid if appropriate) of patients with a range of neurological disorders can trigger consideration of a trial of immunotherapy with the hope of a substantial improvement. A common question, therefore, is ‘how useful is measuring the antibodies during follow-up?’ My answer is usually ‘it can be helpful but only if the antibody levels are calculated carefully, employing serial serum dilutions’. Most commercial and hospital laboratories use single concentrations, designed for sensitivity and specificity, rather than interpretation of treatment responses; even if reported as a titre or in molar terms, the results are seldom suitable for comparisons over time.

It was interesting to see, therefore, that Kojima et al1 were able to predict outcome in 53 AChR-antibody positive myasthenia gravis (MG) patients by testing at first diagnosis and again between 55 and 84 days …

View Full Text

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles